YZFyzfpeptide.comRetatrutide5mgFor Research Use Only
1 / 1
Research product specification
RT5
Retatrutide
For Research Use Only. Not for human or veterinary use.
Retatrutide is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 7 listed specifications. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Volume discounts are available for larger purchasing plans. Please contact us for a quotation.
Delivery includedUsually within 7 days after dispatch
Quality resolutionRefund or replacement when approved
24/7 contactWholesale assistance on WhatsApp
Product profile
About Retatrutide
Retatrutide is a synthetic 39‑amino acid linear peptide and the first‑in‑class triple agonist of the glucose‑dependent insulinotropic polypeptide (GIP), glucagon‑like peptide‑1 (GLP‑1), and glucagon receptors. It operates through a synergistic mechanism that simultaneously activates all three receptors to achieve comprehensive metabolic regulation: GIP and GLP‑1 work together to enhance insulin secretion, suppress appetite, and delay gastric emptying, while glucagon receptor activation further promotes energy expenditure and lipolysis. This triple‑pathway approach endows retatrutide with superior efficacy in weight reduction, glycemic control, and overall metabolic health, surpassing existing dual‑agonist therapies. Its optimized pharmacokinetics enable once‑weekly subcutaneous administration with sustained therapeutic effects.
Main functions
Breakthrough Weight Reduction: Triple‑receptor synergism reduces caloric intake through appetite suppression and satiety enhancement while simultaneously increasing energy expenditure, with clinical data demonstrating significantly greater weight loss compared to GLP‑1‑based and GIP/GLP‑1 dual agonists.
Potential Cardiovascular Benefits: Early‑stage studies indicate improvements in blood pressure and inflammatory markers, providing additional cardiovascular protection.
Once‑Weekly Long‑Acting Regimen: Advanced pharmacokinetic design ensures sustained therapeutic efficacy with a single weekly injection.
Recommended audience
Individuals with severe obesity or overweight who have shown inadequate response to existing weight‑loss medications and require a more potent therapeutic option.
Patients with type 2 diabetes complicated by obesity, needing both exceptional glycemic reduction and substantial weight loss.
Individuals with severe metabolic dysfunction, such as non‑alcoholic steatohepatitis (NASH) or hypertriglyceridemia.
Health‑conscious users pursuing maximal metabolic improvements and open to adopting next‑generation innovative therapies.
Order formatOne box accepted
QuotationConfirmed on WhatsApp
DeliveryShipping and duties included
DocumentationPublished COA or available on request
Research product specification
Product information
Retatrutide is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 7 listed specifications. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Handling information
Storage guidance
Keep unopened lyophilized products protected from light and moisture; store at 2-8°C short term or -20°C long term. After reconstitution, refrigerate according to product documentation and minimize freeze-thaw cycles.
Customer-first resolution
Report quality concerns within 14 days of delivery
Contact us with the order number, batch details and available photos. Opened products are accepted for review. When a quality claim is approved, you may choose a full refund or replacement shipment.
